
News|Videos|November 18, 2026
Executive Conversations: Where Traditional Channel Models Break Down
In Episode 2, Part 2, Cheryl Allen, Nick Calla and Rena Goins discuss where traditional channel models break down as therapies grow more complex.
Advertisement
Advertisement
The second episode of Executive Conversations: The Future of Pharmaceutical Commercialization, presented by Pharmaceutical Commerce, continues with a look at where current channel models are most challenged. Moderator Cheryl Allen, partner at Curatio Advisors, is joined again by Nick Calla, senior vice president of industry relations at Orsini Specialty Pharmacy, and Rena Goins, executive director of commercial trade and distribution at Regeneron Pharmaceuticals.
Related to this article

In Episode 2, Part 1, Cheryl Allen, Nick Calla and Rena Goins discuss whether today's channel models are ready for an increasingly complex pipeline.

In Episode 1, Part 4, Jon Hamrick, Rena Goins and Bob Cochran explain what separates trade teams seen as strategic partners from those that aren't.

In Episode 1, Part 3, Jon Hamrick, Rena Goins and Bob Cochran explain why specialty networks should start small and how to balance access, data and support.

In Episode 1, Part 2, Jon Hamrick, Bob Cochran and Rena Goins explain why trade belongs in commercial planning at least a year before launch.

In Episode 1, Part 1, Jon Hamrick, Rena Goins and Bob Cochran discuss how 340B, the IRA, specialty therapies and launch planning have reshaped the role of commercial trade.

Bob Cochran, former senior director, trade relations at Incyte, discusses direct-to-patient models, specialty launches and distribution strategy.

Jon Hamrick, partner at Curatio Advisors, discusses how product attributes, company size and stakeholder alignment shape pharma commercialization strategy.
Advertisement
Advertisement

